{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:12:20Z","timestamp":1781035940339,"version":"3.54.1"},"reference-count":150,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSAMC"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Neuronal death underlies the symptoms of several human neurological\ndisorders, including Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral\nsclerosis and their precise pathophysiology have not yet been elucidated. According to various\nstudies, the prohibition is the best therapy with neuroprotective approaches, which are advanced\nand safe methods.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This review summarizes some of the already-known and newly emerged neuroprotective\ntargets and strategies and their experimental effects have also been reported. Accordingly, literature\nwas studied from 2000 to 2021, and appropriate articles were searched in Google Scholar and\nScopus with the keywords given in the keywords section of the current review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Lewy bodies are the histopathologic characteristics of neurodegenerative disorders and\nare protein-rich intracellular deposits in which Alpha-Synuclein is its major protein. Alpha-\nSynuclein\u2019s toxic potential provides a compelling rationale for therapeutic strategies aimed at decreasing\nits burden in neuronal cells through numerous pathways, including ubiquitin-proteasome\nsystem and autophagy-lysosome pathway, proteolytic breakdown via cathepsin D, kallikrein-6\n(neurosin), calpain-1 or MMP9, heat shock proteins, and proteolysis targeting chimera which consists\nof a target protein-ligand and an E3 ubiquitin ligase (E3) followed by target protein ubiquitination\n(PROTACs). Other targets that have been noticed recently are the mutant huntingtin, tau\nproteins and glycogen synthase kinase 3\u03b2; their accumulation proceeds extensive neuronal damage\nand up to the minute approach such as Proteolysis Targeting Chimera promotes its degradation in\ncells. Various studies demonstrated that Mendelian gene mutations can result in neurodegenerative\ndiseases. An additional target that has gained much interest is epigenetics, such as mutation, phosphodiesterase,\nRNA binding proteins and Nuclear respiratory factor 1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The novel molecular targets and new strategies compiled and introduced here can be\nused by scientists to design and discover more efficient small molecule drugs against neurodegenerative\ndiseases. And also, the genes in which their mutations can lead to the \u03b1-synuclein aggregation\nor accumulation have been discussed and considered a valuable information on epigenetics in\ndementia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871524922666220616092132","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:37:39Z","timestamp":1655458659000},"page":"88-107","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Molecular Targets and Mechanisms for Neuroprotective Modulation\nin Neurodegenerative Disorders"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-6162","authenticated-orcid":true,"given":"Hamid","family":"Irannejad","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9321","authenticated-orcid":true,"given":"Aala","family":"Azari","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-9404","authenticated-orcid":true,"given":"Amin","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-190X","authenticated-orcid":true,"given":"Behrouz","family":"Jafarkhani","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-4856","authenticated-orcid":true,"given":"Mohammad","family":"Eghbali","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,\nIran"},{"name":"Department of Pharmaceutics, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran\nUniversity of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Karimi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics &amp; Gynecology, Imam Khomeini Hospital, Mazandaran\nUniversity of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-9177","authenticated-orcid":true,"given":"Seyed Sajad","family":"Hosseini Balef","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Institute of Biochemistry and Biophysics,\nUniversity of Tehran, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1331.2005.01202.x","volume":"12","author":"Andlin-Sobocki P.","year":"2005","unstructured":"Andlin-Sobocki P.; Jonsson B.; Wittchen H.U.; Olesen J.; Costs of disorders of the brain in Europe. Eur J Neurol 2005,12(1),1-27","journal-title":"Eur J Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1517\/13543776.13.10.1513","volume":"13","author":"Tan D.X.","year":"2003","unstructured":"Tan D.X.; Manchester L.C.; Sainz R.; Mayo J.C.; Alvares F.L.; Reiter R.J.; Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin Ther Pat 2003,13(10),1513-1543","journal-title":"Expert Opin Ther Pat"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2478\/v10136-011-0013-4","volume":"9","author":"Nieoullon A.","year":"2011","unstructured":"Nieoullon A.; Neurodegenerative diseases and neuroprotection: current views and prospects. J Appl Biomed 2011,9(4),173-183","journal-title":"J Appl Biomed"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.bbrc.2016.08.043","volume":"483","author":"Agarwal S.","year":"2017","unstructured":"Agarwal S.; Yadav A.; Chaturvedi R.K.; Peroxisome Proliferator-Activated Receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun 2017,483(4),1166-1177","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/NEN.0b013e3181ac10a7","volume":"68","author":"Markesbery W.R.","year":"2009","unstructured":"Markesbery W.R.; Jicha G.A.; Liu H.; Schmitt F.A.; Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009,68(7),816-822","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.3390\/ijms21134718","volume":"21","author":"Urbizu A.","year":"2020","unstructured":"Urbizu A.; Beyer K.; Epigenetics in lewy body diseases: Impact on gene expression, utility as a biomarker, and possibilities for therapy. Int J Mol Sci 2020,21(13),4718","journal-title":"Int J Mol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","volume":"27","author":"Wakabayashi K.","year":"2007","unstructured":"Wakabayashi K.; Tanji K.; Mori F.; Takahashi H.; The lewy body in Parkinson\u2019s disease: molecules implicated in the formation and degradation of &#x3B1;-synuclein aggregates. Neuropathology 2007,27(5),494-506","journal-title":"Neuropathology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/brain\/awm318","volume":"131","author":"Pan T.","year":"2008","unstructured":"Pan T.; Kondo S.; Le W.; Jankovic J.; The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson\u2019s disease. Brain 2008,131(Pt 8),1969-1978","journal-title":"Brain"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1073\/pnas.1620159114","volume":"114","author":"Pineda A.","year":"2017","unstructured":"Pineda A.; Burr&#xE9; J.; Modulating membrane binding of &#x3B1;-synuclein as a therapeutic strategy. Proc Natl Acad Sci USA 2017,114(6),1223-1225","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e9313","DOI":"10.1371\/journal.pone.0009313","volume":"5","author":"Crews L.","year":"2010","unstructured":"Crews L.; Spencer B.; Desplats P.; Patrick C.; Paulino A.; Rockenstein E.; Hansen L.; Adame A.; Galasko D.; Masliah E.; Selective molecular alterations in the autophagy pathway in patients with lewy body disease and in models of &#x3B1;-synucleinopathy. PLoS One 2010,5(2),e9313","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e52868","DOI":"10.1371\/journal.pone.0052868","volume":"7","author":"Watanabe Y.","year":"2012","unstructured":"Watanabe Y.; Tatebe H.; Taguchi K.; Endo Y.; Tokuda T.; Mizuno T.; Nakagawa M.; Tanaka M.; p62\/SQSTM1-dependent autophagy of lewy body-like &#x3B1;-synuclein inclusions. PLoS One 2012,7(12),e52868","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"11530","DOI":"10.1002\/anie.201706529","volume":"56","author":"Tomoshige S.","year":"2017","unstructured":"Tomoshige S.; Nomura S.; Ohgane K.; Hashimoto Y.; Ishikawa M.; Discovery of small molecules that induce the degradation of huntingtin. Angew Chem Int Ed Engl 2017,56(38),11530-11533","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","volume":"11","author":"Kargbo R.B.","year":"2020","unstructured":"Kargbo R.B.; PROTAC compounds targeting &#x3B1;-synuclein protein for treating neurogenerative disorders: Alzheimer\u2019s and Parkinson\u2019s diseases. ACS Med Chem Lett 2020,11(6),1086-1087","journal-title":"ACS Med Chem Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","volume":"63","author":"Gatz M.","year":"2006","unstructured":"Gatz M.; Reynolds C.A.; Fratiglioni L.; Johansson B.; Mortimer J.A.; Berg S.; Fiske A.; Pedersen N.L.; Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006,63(2),168-174","journal-title":"Arch Gen Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"Van Cauwenberghe C.","year":"2016","unstructured":"Van Cauwenberghe C.; Van Broeckhoven C.; Sleegers K.; The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016,18(5),421-430","journal-title":"Genet Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp.2010.207464","volume":"81","author":"Al-Chalabi A.","year":"2010","unstructured":"Al-Chalabi A.; Fang F.; Hanby M.F.; Leigh P.N.; Shaw C.E.; Ye W.; An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010,81(12),1324-1326","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1074\/jbc.M114.620484","volume":"290","author":"Cheruvara H.","year":"2015","unstructured":"Cheruvara H.; Allen-Baume V.L.; Kad N.M.; Mason J.M.; Intracellular screening of a peptide library to derive a potent peptide inhibitor of &#x3B1;-synuclein aggregation. J Biol Chem 2015,290(12),7426-7435","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1750-1326-4-9","volume":"4","author":"Cookson M.R.","year":"2009","unstructured":"Cookson M.R.; Alpha-synuclein and neuronal cell death. Mol Neurodegener 2009,4(14),9","journal-title":"Mol Neurodegener"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jmb.2009.10.021","volume":"394","author":"Van Rooijen B.D.","year":"2009","unstructured":"Van Rooijen B.D.; Van Leijenhorst-Groener K.A.; Claessens M.M.A.E.; Subramaniam V.; Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers. J Mol Biol 2009,394(5),826-833","journal-title":"J Mol Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1002\/ange.201400491","volume":"126","author":"Paslawski W.","year":"2014","unstructured":"Paslawski W.; Mysling S.; Thomsen K.; J&#xF8;rgensen T.J.D.; Otzen D.E.; Co-existence of two different &#x3B1;-synuclein oligomers with different core structures determined by hydrogen\/deuterium exchange mass spectrometry. Angew Chem 2014,126(29),7690-7693","journal-title":"Angew Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"Dehay B.","year":"2015","unstructured":"Dehay B.; Bourdenx M.; Gorry P.; Przedborski S.; Vila M.; Hunot S.; Singleton A.; Olanow C.W.; Merchant K.M.; Bezard E.; Petsko G.A.; Meissner W.G.; Targeting &#x3B1;-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 2015,14(8),855-866","journal-title":"Lancet Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","volume":"35","author":"Chu Y.","year":"2009","unstructured":"Chu Y.; Dodiya H.; Aebischer P.; Olanow C.W.; Kordower J.H.; Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009,35(3),385-398","journal-title":"Neurobiol Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/nan.12512","volume":"45","author":"Kiely A.P.","year":"2019","unstructured":"Kiely A.P.; Miners J.S.; Courtney R.; Strand C.; Love S.; Holton J.L.; Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of &#x3B1;-synuclein in multiple system atrophy. Neuropathol Appl Neurobiol 2019,45(4),347-360","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrd2056","volume":"5","author":"Nalepa G.","year":"2006","unstructured":"Nalepa G.; Rolfe M.; Harper J.W.; Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006,5(7),596-613","journal-title":"Nat Rev Drug Discov"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ptr.5834","volume":"31","author":"Wang Z.Y.","year":"2017","unstructured":"Wang Z.Y.; Liu J.Y.; Yang C.B.; Malampati S.; Huang Y.Y.; Li M.X.; Li M.; Song J.X.; Neuroprotective natural products for the treatment of Parkinson\u2019s disease by targeting the autophagy-lysosome pathway: A systematic review. Phytother Res 2017,31(8),1119-1127","journal-title":"Phytother Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11910-007-0068-5","volume":"7","author":"Ventruti A.","year":"2007","unstructured":"Ventruti A.; Cuervo A.M.; Autophagy and neurodegeneration. Curr Neurol Neurosci Rep 2007,7(5),443-451","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0070-2153(05)73007-6","volume":"73","author":"Massey A.C.","year":"2006","unstructured":"Massey A.C.; Zhang C.; Cuervo A.M.; Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol 2006,73,205-235","journal-title":"Curr Top Dev Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-6606-2-5","volume":"2","author":"Cullen V.","year":"2009","unstructured":"Cullen V.; Lindfors M.; Ng J.; Paetau A.; Swinton E.; Kolodziej P.; Boston H.; Saftig P.; Woulfe J.; Feany M.B.; Myllykangas L.; Schlossmacher M.G.; Tyynel&#xE4; J.; Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain 2009,2(1),5","journal-title":"Mol Brain"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1126\/science.273.5274.501","volume":"273","author":"Cuervo A.M.","year":"1996","unstructured":"Cuervo A.M.; Dice J.F.; A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996,273(5274),501-503","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.biocel.2004.02.013","volume":"36","author":"Majeski A.E.","year":"2004","unstructured":"Majeski A.E.; Dice J.F.; Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol 2004,36(12),2435-2444","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"23542","DOI":"10.1074\/jbc.M801992200","volume":"283","author":"Vogiatzi T.","year":"2008","unstructured":"Vogiatzi T.; Xilouri M.; Vekrellis K.; Stefanis L.; Wild type &#x3B1;-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008,283(35),23542-23556","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"Cuervo A.M.","year":"2004","unstructured":"Cuervo A.M.; Stefanis L.; Fredenburg R.; Lansbury P.T.; Sulzer D.; Impaired degradation of mutant &#x3B1;-synuclein by chaperone-mediated autophagy. Science 2004,305(5688),1292-1295","journal-title":"Science"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1523\/JNEUROSCI.1560-11.2011","volume":"31","author":"Ebrahimi-Fakhari D.","year":"2011","unstructured":"Ebrahimi-Fakhari D.; Cantuti-Castelvetri I.; Fan Z.; Rockenstein E.; Masliah E.; Hyman B.T.; McLean P.J.; Unni V.K.; Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of &#x3B1;-synuclein. J Neurosci 2011,31(41),14508-14520","journal-title":"J Neurosci"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2210","volume":"8","author":"Ghosh A.","year":"2016","unstructured":"Ghosh A.; Tyson T.; George S; Hildebrandt E.N.; Steiner J.A.; Madaj Z.; Mitochondrial pyruvate carrier regulates autophagy, inflammation,  and neurodegeneration in experimental models of Parkinson\u2019s  disease. Sci. Tansl. Med. 368ra1742016,8(368)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-019-0159-7","volume":"8","author":"Wu J.Z.","year":"2019","unstructured":"Wu J.Z.; Ardah M.; Haikal C.; Svanbergsson A.; Diepenbroek M.; Vaikath N.N.; Li W.; Wang Z.Y.; Outeiro T.F.; El-Agnaf O.M.; Li J.Y.; Dihydromyricetin and salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Transl Neurodegener 2019,8(1),18","journal-title":"Transl Neurodegener"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"127821","DOI":"10.1016\/j.bmcl.2021.127821","volume":"36","author":"Fiolek T.J.","year":"2021","unstructured":"Fiolek T.J.; Magyar C.L.; Wall T.J.; Davies S.B.; Campbell M.V.; Savich C.J.; Tepe J.J.; Mosey R.A.; Dihydroquinazolines enhance 20S proteasome activity and induce degradation of &#x3B1;-synuclein, an intrinsically disordered protein associated with neurodegeneration. Bioorg Med Chem Lett 2021,36,127821","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"Hebron M.L.","year":"2013","unstructured":"Hebron M.L.; Lonskaya I.; Moussa C.E.H.; Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of &#x3B1;-synuclein in Parkinson\u2019s disease models. Hum Mol Genet 2013,22(16),3315-3328","journal-title":"Hum Mol Genet"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.neurobiolaging.2014.01.027","volume":"35","author":"H&#xF6;llerhage M.","year":"2014","unstructured":"H&#xF6;llerhage M.; Goebel J.N.; de Andrade A.; Hildebrandt T.; Dolga A.; Culmsee C.; Oertel W.H.; Hengerer B.; H&#xF6;glinger G.U.; Trifluoperazine rescues human dopaminergic cells from wild-type &#x3B1;-synuclein-induced toxicity. Neurobiol Aging 2014,35(7),1700-1711","journal-title":"Neurobiol Aging"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1038\/s41598-018-25118-z","volume":"8","author":"Macedo D.","year":"2018","unstructured":"Macedo D.; Jardim C.; Figueira I.; Almeida A.F.; McDougall G.J.; Stewart D.; Yuste J.E.; Tom&#xE1;s-Barber&#xE1;n F.A.; Tenreiro S.; Outeiro T.F.; Santos C.N.; (Poly)phenol-digested metabolites modulate alpha-synuclein toxicity by regulating proteostasis. Sci Rep 2018,8(1),6965","journal-title":"Sci Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","volume":"53","author":"He Q.","year":"2016","unstructured":"He Q.; Koprich J.B.; Wang Y.; Yu W.B.; Xiao B.G.; Brotchie J.M.; Wang J.; Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV $&#x3B1;$-synuclein rat model of Parkinson\u2019s disease. Mol Neurobiol 2016,53(4),2258-2268","journal-title":"Mol Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"77706","DOI":"10.1039\/C5RA13546J","volume":"5","author":"Kaur S.","year":"2015","unstructured":"Kaur S.; Nazir A.; Potential role of protein stabilizers in amelioration of Parkinson\u2019s disease and associated effects in transgenic Caenorhabditis elegans model expressing alpha-synuclein. RSC Advances 2015,5(95),77706-77715","journal-title":"RSC Advances"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1046\/j.1471-4159.2002.01190.x","volume":"83","author":"McLean P.J.","year":"2002","unstructured":"McLean P.J.; Kawamata H.; Shariff S.; Hewett J.; Sharma N.; Ueda K.; Breakefield X.O.; Hyman B.T.; TorsinA and heat shock proteins act as molecular chaperones: suppression of &#x3B1;-synuclein aggregation. J Neurochem 2002,83(4),846-854","journal-title":"J Neurochem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bbrc.2006.10.085","volume":"351","author":"Outeiro T.F.","year":"2006","unstructured":"Outeiro T.F.; Klucken J.; Strathearn K.E.; Liu F.; Nguyen P.; Rochet J.C.; Hyman B.T.; McLean P.J.; Small heat shock proteins protect against &#x3B1;-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 2006,351(3),631-638","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"25497","DOI":"10.1074\/jbc.M400255200","volume":"279","author":"Klucken J.","year":"2004","unstructured":"Klucken J.; Shin Y.; Masliah E.; Hyman B.T.; McLean P.J.; Hsp70 reduces $&#x3B1;$-synuclein aggregation and toxicity. J Biol Chem 2004,279(24),25497-25502","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbrc.2004.07.021","volume":"321","author":"McLean P.J.","year":"2004","unstructured":"McLean P.J.; Klucken J.; Shin Y.; Hyman B.T.; Geldanamycin induces Hsp70 and prevents &#x3B1;-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 2004,321(3),665-669","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1016\/j.jmb.2013.08.006","volume":"425","author":"Daturpalli S.","year":"2013","unstructured":"Daturpalli S.; Waudby C.A.; Meehan S.; Jackson S.E.; Hsp90 inhibits &#x3B1;-synuclein aggregation by interacting with soluble oligomers. J Mol Biol 2013,425(22),4614-4628","journal-title":"J Mol Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1074\/jbc.M412106200","volume":"280","author":"Auluck P.K.","year":"2005","unstructured":"Auluck P.K.; Meulener M.C.; Bonini N.M.; Mechanisms of suppression of $&#x3B1;$-synuclein neurotoxicity by geldanamycin in drosophila. J Biol Chem 2005,280(4),2873-2878","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1124\/jpet.109.158436","volume":"332","author":"Putcha P.","year":"2010","unstructured":"Putcha P.; Danzer K.M.; Kranich L.R.; Scott A.; Silinski M.; Mabbett S.; Hicks C.D.; Veal J.M.; Steed P.M.; Hyman B.T.; McLean P.J.; Brain-permeable small-molecule inhibitors of Hsp90 prevent &#x3B1;-synuclein oligomer formation and rescue &#x3B1;-synuclein-induced toxicity. J Pharmacol Exp Ther 2010,332(3),849-857","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"Migdalska-Richards A.","year":"2016","unstructured":"Migdalska-Richards A.; Daly L.; Bezard E.; Schapira A.H.V.; Ambroxol effects in glucocerebrosidase and &#x3B1;-synuclein transgenic mice. Ann Neurol 2016,80(5),766-775","journal-title":"Ann Neurol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/S0021-9258(19)85585-0","volume":"255","author":"Hasilik A.","year":"1980","unstructured":"Hasilik A.; Neufeld E.F.; Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J Biol Chem 1980,255(10),4937-4945","journal-title":"J Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbrc.2020.06.155","volume":"529","author":"McGlinchey R.P.","year":"2020","unstructured":"McGlinchey R.P.; Lacy S.M.; Walker R.L.; Lee J.C.; Cathepsin K is a potent disaggregase of &#x3B1;-synuclein fibrils. Biochem Biophys Res Commun 2020,529(4),1106-1111","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1756-6606-1-17","volume":"1","author":"Qiao L.","year":"2008","unstructured":"Qiao L.; Hamamichi S.; Caldwell K.A.; Caldwell G.A.; Yacoubian T.A.; Wilson S.; Xie Z.L.; Speake L.D.; Parks R.; Crabtree D.; Liang Q.; Crimmins S.; Schneider L.; Uchiyama Y.; Iwatsubo T.; Zhou Y.; Peng L.; Lu Y.; Standaert D.G.; Walls K.C.; Shacka J.J.; Roth K.A.; Zhang J.; Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain 2008,1(1),17","journal-title":"Mol Brain"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"McGlinchey R.P.","year":"2015","unstructured":"McGlinchey R.P.; Lee J.C.; Cysteine cathepsins are essential in lysosomal degradation of &#x3B1;-synuclein. Proc Natl Acad Sci USA 2015,112(30),9322-9327","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1177\/002215540104901111","volume":"49","author":"Petraki C.D.","year":"2001","unstructured":"Petraki C.D.; Karavana V.N.; Skoufogiannis P.T.; Little S.P.; Howarth D.J.C.; Yousef G.M.; The spectrum of human kallikrein 6 (zyme\/protease M\/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001,49(11),1431-1441","journal-title":"J Histochem Cytochem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/hmg\/ddg283","volume":"12","author":"Iwata A.","year":"2003","unstructured":"Iwata A.; Maruyama M.; Akagi T.; Hashikawa T.; Kanazawa I.; Tsuji S.; Nukina N.; Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 2003,12(20),2625-2635","journal-title":"Hum Mol Genet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neures.2010.04.008","volume":"67","author":"Tatebe H.","year":"2010","unstructured":"Tatebe H.; Watanabe Y.; Kasai T.; Mizuno T.; Nakagawa M.; Tanaka M.; Tokuda T.; Extracellular neurosin degrades &#x3B1;-synuclein in cultured cells. Neurosci Res 2010,67(4),341-346","journal-title":"Neurosci Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","volume":"10","author":"Spencer B.","year":"2015","unstructured":"Spencer B.; Valera E.; Rockenstein E.; Trejo-Morales M.; Adame A.; Masliah E.; A brain-targeted, modified neurosin (kallikrein-6) reduces &#x3B1;-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener 2015,10(1),48","journal-title":"Mol Neurodegener"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/mt.2012.66","volume":"21","author":"Spencer B.","year":"2013","unstructured":"Spencer B.; Michael S.; Shen J.; Kosberg K.; Rockenstein E.; Patrick C.; Adame A.; Masliah E.; Lentivirus mediated delivery of neurosin promotes clearance of wild-type &#x3B1;-synuclein and reduces the pathology in an &#x3B1;-synuclein model of LBD. Mol Ther 2013,21(1),31-41","journal-title":"Mol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1096\/fj.13-245852","volume":"28","author":"Ximerakis M.","year":"2014","unstructured":"Ximerakis M.; Pampalakis G.; Roumeliotis T.I.; Sykioti V-S.; Garbis S.D.; Stefanis L.; Sotiropoulou G.; Vekrellis K.; Resistance of naturally secreted &#x3B1;-synuclein to proteolysis. FASEB J 2014,28(7),3146-3158","journal-title":"FASEB J"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"14502","DOI":"10.18632\/oncotarget.13264","volume":"8","author":"Pampalakis G.","year":"2017","unstructured":"Pampalakis G.; Sykioti V-S.; Ximerakis M.; Stefanakou-Kalakou I.; Melki R.; Vekrellis K.; Sotiropoulou G.; KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget 2017,8(9),14502-14515","journal-title":"Oncotarget"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","volume":"114","author":"Perni M.","year":"2017","unstructured":"Perni M.; Galvagnion C.; Maltsev A.; Meisl G.; M&#xFC;ller M.B.D.; Challa P.K.; Kirkegaard J.B.; Flagmeier P.; Cohen S.I.; Cascella R.; Chen S.W.; Limbocker R.; Sormanni P.; Heller G.T.; Aprile F.A.; Cremades N.; Cecchi C.; Chiti F.; Nollen E.A.; Knowles T.P.; Vendruscolo M.; Bax A.; Zasloff M.; Dobson C.M.; A natural product inhibits the initiation of &#x3B1;-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA 2017,114(6),E1009-E1017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nbd.2013.12.011","volume":"64","author":"Davies S.E.","year":"2014","unstructured":"Davies S.E.; Hallett P.J.; Moens T.; Smith G.; Mangano E.; Kim H.T.; Goldberg A.L.; Liu J.L.; Isacson O.; Tofaris G.K.; Enhanced ubiquitin-dependent degradation by Nedd4 protects against &#x3B1;-synuclein accumulation and toxicity in animal models of Parkinson\u2019s disease. Neurobiol Dis 2014,64,79-87","journal-title":"Neurobiol Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0955-0674(95)80031-X","volume":"7","author":"Hochstrasser M.","year":"1995","unstructured":"Hochstrasser M.; Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995,7(2),215-223","journal-title":"Curr Opin Cell Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.tcb.2015.03.002","volume":"25","author":"Clague M.J.","year":"2015","unstructured":"Clague M.J.; Heride C.; Urb&#xE9; S.; The demographics of the ubiquitin system. Trends Cell Biol 2015,25(7),417-426","journal-title":"Trends Cell Biol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"Vassilev L.T.","year":"2004","unstructured":"Vassilev L.T.; Vu B.T.; Graves B.; Carvajal D.; Podlaski F.; Filipovic Z.; Kong N.; Kammlott U.; Lukacs C.; Klein C.; Fotouhi N.; Liu E.A.; \nIn vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004,303(5659),844-848","journal-title":"Science"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/acsmedchemlett.9b00083","volume":"10","author":"Kargbo R.B.","year":"2019","unstructured":"Kargbo R.B.; Treatment of Alzheimer\u2019s by PROTAC-tau protein degradation. ACS Med Chem Lett 2019,10(5),699-700","journal-title":"ACS Med Chem Lett"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1074\/jbc.M008919200","volume":"276","author":"Giasson B.I.","year":"2001","unstructured":"Giasson B.I.; Murray I.V.; Trojanowski J.Q.; Lee V.M.Y.; A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001,276(4),2380-2386","journal-title":"J Biol Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1021\/acschemneuro.0c00528","volume":"11","author":"Eskandari H.","year":"2020","unstructured":"Eskandari H.; Ghanadian M.; Noleto-Dias C.; Lomax C.; Tawfike A.; Christiansen G.; Sutherland D.S.; Ward J.L.; Mohammad-Beigi H.; Otzen D.E.; Inhibitors of $\\alpha$-synuclein fibrillation and oligomer toxicity in Rosa damascen: The all-pervading powers of flavonoids and phenolic glycosides. ACS Chem Neurosci 2020,11(19),3161-3173","journal-title":"ACS Chem Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e1006593","DOI":"10.1371\/journal.pgen.1006593","volume":"13","author":"Kerr F.","year":"2017","unstructured":"Kerr F.; Sofola-Adesakin O.; Ivanov D.K.; Gatliff J.; Gomez Perez-Nievas B.; Bertrand H.C.; Martinez P.; Callard R.; Snoeren I.; Cochem&#xE9; H.M.; Adcott J.; Khericha M.; Castillo-Quan J.I.; Wells G.; Noble W.; Thornton J.; Partridge L.; Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer\u2019s disease. PLoS Genet 2017,13(3),e1006593","journal-title":"PLoS Genet"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s12035-017-0496-4","volume":"55","author":"Siracusa R.","year":"2018","unstructured":"Siracusa R.; Paterniti I.; Cordaro M.; Crupi R.; Bruschetta G.; Campolo M.; Cuzzocrea S.; Esposito E.; Neuroprotective effects of temsirolimus in animal models of Parkinson\u2019s disease. Mol Neurobiol 2018,55(3),2403-2419","journal-title":"Mol Neurobiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acs.jnatprod.8b00610","volume":"82","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Jovcevski B.; Pukala T.L.; C-phycocyanin from spirulina inhibits $\\alpha$-synuclein and amyloid-$\\beta$ fibril formation but not amorphous aggregation. J Nat Prod 2019,82(1),66-73","journal-title":"J Nat Prod"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/cn3001203","volume":"4","author":"Singh P.K.","year":"2013","unstructured":"Singh P.K.; Kotia V.; Ghosh D.; Mohite G.M.; Kumar A.; Maji S.K.; Curcumin modulates &#x3B1;-synuclein aggregation and toxicity. ACS Chem Neurosci 2013,4(3),393-407","journal-title":"ACS Chem Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"Anand P.","year":"2007","unstructured":"Anand P.; Kunnumakkara A.B.; Newman R.A.; Aggarwal B.B.; Bioavailability of curcumin: Problems and promises. Mol Pharm 2007,4(6),807-818","journal-title":"Mol Pharm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1074\/jbc.M111.325548","volume":"287","author":"Ahmad B.","year":"2012","unstructured":"Ahmad B.; Lapidus L.J.; Curcumin prevents aggregation in &#x3B1;-synuclein by increasing reconfiguration rate. J Biol Chem 2012,287(12),9193-9199","journal-title":"J Biol Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/cbdd.12435","volume":"85","author":"Irannejad H.","year":"2015","unstructured":"Irannejad H.; Unsal Tan O.; Ozadali K.; Dadashpour S.; Tuylu Kucukkilinc T.; Ahangar N.; Ahmadnejad M.; Emami S.; 1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and &#x3B2;-amyloid aggregation inhibitors: Biological evaluation and in silico study. Chem Biol Drug Des 2015,85(4),494-503","journal-title":"Chem Biol Drug Des"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ardp.201400400","volume":"348","author":"Dadashpour S.","year":"2015","unstructured":"Dadashpour S.; Tuylu Kucukkilinc T.; Unsal Tan O.; Ozadali K.; Irannejad H.; Emami S.; Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and &#x3B2;-amyloid aggregation inhibitors. Arch Pharm 2015,348(3),179-187","journal-title":"Arch Pharm"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00044-017-2003-x","volume":"26","author":"Tuylu Kucukkilinc T.","year":"2017","unstructured":"Tuylu Kucukkilinc T.; Safari Yanghagh K.; Ayazgok B.; Ali Roknipour M.; Homayouni Moghadam F.; Moradi A.; Emami S.; Amini M.; Irannejad H.; Synthesis and neuroprotective activity of novel 1,2,4-triazine derivatives with ethyl acetate moiety against H2O2 and A&#x3B2;-induced neurotoxicity. Med Chem Res 2017,26(11),3057-3071","journal-title":"Med Chem Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/jhg.2010.13","volume":"55","author":"Hamza T.H.","year":"2010","unstructured":"Hamza T.H.; Payami H.; The heritability of risk and age at onset of Parkinson\u2019s disease after accounting for known genetic risk factors. J Hum Genet 2010,55(4),241-243","journal-title":"J Hum Genet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrn1971","volume":"7","author":"Pasinelli P.","year":"2006","unstructured":"Pasinelli P.; Brown R.H.; Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci 2006,7(9),710-723","journal-title":"Nat Rev Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1172\/JCI24761","volume":"115","author":"Bertram L.","year":"2005","unstructured":"Bertram L.; Tanzi R.E.; The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005,115(6),1449-1457","journal-title":"J Clin Invest"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2950.e1","DOI":"10.1016\/j.neurobiolaging.2012.07.004","volume":"33","author":"Van Blitterswijk M.","year":"2012","unstructured":"Van Blitterswijk M.; Van Es M.A.; Koppers M.; Van Rheenen W.; Medic J.; Schelhaas H.J.; Van Der Kooi A.J.; De Visser M.; Veldink J.H.; Van Den Berg L.H.; VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol Aging 2012,33(12),2950.e1-2950.e4","journal-title":"Neurobiol Aging"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41588-018-0070-7","volume":"50","author":"Kramer N.J.","year":"2018","unstructured":"Kramer N.J.; Haney M.S.; Morgens D.W.; Jovi&#x10D;i\u0107 A.; Couthouis J.; Li A.; Ousey J.; Ma R.; Bieri G.; Tsui C.K.; Shi Y.; Hertz N.T.; Tessier-Lavigne M.; Ichida J.K.; Bassik M.C.; Gitler A.D.; CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat Genet 2018,50(4),603-612","journal-title":"Nat Genet"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"Kim J.","year":"2009","unstructured":"Kim J.; Castellano J.M.; Jiang H.; Basak J.M.; Parsadanian M.; Pham V.; Mason S.M.; Paul S.M.; Holtzman D.M.; Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A &#x3B2; clearance. Neuron 2009,64(5),632-644","journal-title":"Neuron"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"Glenner G.G.","year":"1984","unstructured":"Glenner G.G.; Wong C.W.; Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984,120(3),885-890","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000077158","volume":"17","author":"Ostojic J.","year":"2004","unstructured":"Ostojic J.; Elfgren C.; Passant U.; Nilsson K.; Gustafson L.; Lannfelt L.; Froelich Fabre S.; The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord 2004,17(4),298-301","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/humu.10269","volume":"22","author":"Rademakers R.","year":"2003","unstructured":"Rademakers R.; Dermaut B.; Peeters K.; Cruts M.; Heutink P.; Goate A.; Van Broeckhoven C.; Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer\u2019s disease does not share a common founder in Western Europe. Hum Mutat 2003,22(5),409-411","journal-title":"Hum Mutat"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1086\/491749","volume":"77","author":"Rademakers R.","year":"2005","unstructured":"Rademakers R.; Cruts M.; Sleegers K.; Dermaut B.; Theuns J.; Aulchenko Y.; Weckx S.; De Pooter T.; Van den Broeck M.; Corsmit E.; De Rijk P.; Del-Favero J.; Van Swieten J.; Van Duijn C.M.; Van Broeckhoven C.; Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a dutch population-based sample. Am J Hum Genet 2005,77(4),643-652","journal-title":"Am J Hum Genet"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00415-005-0799-7","volume":"252","author":"Sala Frigerio C.","year":"2005","unstructured":"Sala Frigerio C.; Piscopo P.; Calabrese E.; Crestini A.; Malvezzi Campeggi L.; Civita di Fava R.; Fogliarino S.; Albani D.; Marcon G.; Cherchi R.; Piras R.; Forloni G.; Confaloni A.; PEN-2 gene mutation in a familial Alzheimer\u2019s disease case. J Neurol 2005,252(9),1033-1036","journal-title":"J Neurol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","volume":"2","author":"Tanzi R.E.","year":"2012","unstructured":"Tanzi R.E.; The genetics of Alzheimer\u2019s disease. Cold Spring Harb Perspect Med 2012,2(10),a006296","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"Strittmatter W.J.","year":"1993","unstructured":"Strittmatter W.J.; Saunders A.M.; Schmechel D.; Pericak-Vance M.; Enghild J.; Salvesen G.S.; Roses A.D.; Apolipoprotein E.; High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer\u2019s disease. Proc Natl Acad Sci USA 1993,90(5),1977-1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"Corder E.H.","year":"1994","unstructured":"Corder E.H.; Saunders A.M.; Risch N.J.; Strittmatter W.J.; Schmechel D.E.; Gaskell P.C.; \n; Rimmler, J.B.; Locke, P.A.; Conneally, P.M.; Schmader, K.E.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer\u2019s disease. Nat Genet 1994,7(2),180-184","journal-title":"Nat Genet"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-2007-12402","volume":"12","author":"Gr&#xFC;nblatt E.","year":"2007","unstructured":"Gr&#xFC;nblatt E.; Zander N.; Bartl J.; Jie L.; Monoranu C-M.; Arzberger T.; Ravid R.; Roggendorf W.; Gerlach M.; Riederer P.; Comparison analysis of gene expression patterns between sporadic Alzheimer\u2019s and Parkinson\u2019s disease. J Alzheimers Dis 2007,12(4),291-311","journal-title":"J Alzheimers Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"Renton A.E.","year":"2014","unstructured":"Renton A.E.; Chi&#xF2; A.; Traynor B.J.; State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014,17(1),17-23","journal-title":"Nat Neurosci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00401-014-1251-9","volume":"127","author":"Cooper-Knock J.","year":"2014","unstructured":"Cooper-Knock J.; Shaw P.J.; Kirby J.; The widening spectrum of C9ORF72-related disease: Genotype\/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 2014,127(3),333-345","journal-title":"Acta Neuropathol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"DeJesus-Hernandez M.","year":"2011","unstructured":"DeJesus-Hernandez M.; Mackenzie I.R.; Boeve B.F.; Boxer A.L.; Baker M.; Rutherford N.J.; Nicholson A.M.; Finch N.A.; Flynn H.; Adamson J.; Kouri N.; Wojtas A.; Sengdy P.; Hsiung G.Y.; Karydas A.; Seeley W.W.; Josephs K.A.; Coppola G.; Geschwind D.H.; Wszolek Z.K.; Feldman H.; Knopman D.S.; Petersen R.C.; Miller B.L.; Dickson D.W.; Boylan K.B.; Graff-Radford N.R.; Rademakers R.; Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011,72(2),245-256","journal-title":"Neuron"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"Renton A.E.","year":"2011","unstructured":"Renton A.E.; Majounie E.; Waite A.; Sim&#xF3;n-S&#xE1;nchez J.; Rollinson S.; Gibbs J.R.; Schymick J.C.; Laaksovirta H.; van Swieten J.C.; Myllykangas L.; Kalimo H.; Paetau A.; Abramzon Y.; Remes A.M.; Kaganovich A.; Scholz S.W.; Duckworth J.; Ding J.; Harmer D.W.; Hernandez D.G.; Johnson J.O.; Mok K.; Ryten M.; Trabzuni D.; Guerreiro R.J.; Orrell R.W.; Neal J.; Murray A.; Pearson J.; Jansen I.E.; Sondervan D.; Seelaar H.; Blake D.; Young K.; Halliwell N.; Callister J.B.; Toulson G.; Richardson A.; Gerhard A.; Snowden J.; Mann D.; Neary D.; Nalls M.A.; Peuralinna T.; Jansson L.; Isoviita V.M.; Kaivorinne A.L.; H&#xF6;ltt&#xE4;-Vuori M.; Ikonen E.; Sulkava R.; Benatar M.; Wuu J.; Chi&#xF2; A.; Restagno G.; Borghero G.; Sabatelli M.; Heckerman D.; Rogaeva E.; Zinman L.; Rothstein J.D.; Sendtner M.; Drepper C.; Eichler E.E.; Alkan C.; Abdullaev Z.; Pack S.D.; Dutra A.; Pak E.; Hardy J.; Singleton A.; Williams N.M.; Heutink P.; Pickering-Brown S.; Morris H.R.; Tienari P.J.; Traynor B.J.; A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011,72(2),257-268","journal-title":"Neuron"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ng.132","volume":"40","author":"Kabashi E.","year":"2008","unstructured":"Kabashi E.; Valdmanis P.N.; Dion P.; Spiegelman D.; McConkey B.J.; TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008,40,572-574","journal-title":"Nat Genet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","volume":"319","author":"Sreedharan J.","year":"2008","unstructured":"Sreedharan J.; Blair I.P.; Tripathi V.B.; Hu X.; Vance C.; Rogelj B.; Ackerley S.; Durnall J.C.; Williams K.L.; Buratti E.; Baralle F.; de Belleroche J.; Mitchell J.D.; Leigh P.N.; Al-Chalabi A.; Miller C.C.; Nicholson G.; Shaw C.E.; TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008,319(5870),1668-1672","journal-title":"Science"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"Kwiatkowski T.J.","year":"2009","unstructured":"Kwiatkowski T.J.; Bosco D.A.; Leclerc A.L.; Tamrazian E.; Vanderburg C.R.; Russ C.; Davis A.; Gilchrist J.; Kasarskis E.J.; Munsat T.; Valdmanis P.; Rouleau G.A.; Hosler B.A.; Cortelli P.; de Jong P.J.; Yoshinaga Y.; Haines J.L.; Pericak-Vance M.A.; Yan J.; Ticozzi N.; Siddique T.; McKenna-Yasek D.; Sapp P.C.; Horvitz H.R.; Landers J.E.; Brown R.H.; Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009,323(5918),1205-1208","journal-title":"Science"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"Vance C.","year":"2009","unstructured":"Vance C.; Rogelj B.; Hortob&#xE1;gyi T.; De Vos K.J.; Nishimura A.L.; Sreedharan J.; Hu X.; Smith B.; Ruddy D.; Wright P.; Ganesalingam J.; Williams K.L.; Tripathi V.; Al-Saraj S.; Al-Chalabi A.; Leigh P.N.; Blair I.P.; Nicholson G.; De Belleroche J.; Gallo J.M.; Miller C.C.; Shaw C.E.; Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009,323(5918),1208-1211","journal-title":"Science"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nn.3688","volume":"17","author":"Johnson J.O.","year":"2014","unstructured":"Johnson J.O.; Pioro E.P.; Boehringer A.; Chia R.; Feit H.; Renton A.E.; Pliner H.A.; Abramzon Y.; Marangi G.; Winborn B.J.; Gibbs J.R.; Nalls M.A.; Morgan S.; Shoai M.; Hardy J.; Pittman A.; Orrell R.W.; Malaspina A.; Sidle K.C.; Fratta P.; Harms M.B.; Baloh R.H.; Pestronk A.; Weihl C.C.; Rogaeva E.; Zinman L.; Drory V.E.; Borghero G.; Mora G.; Calvo A.; Rothstein J.D.; Drepper C.; Sendtner M.; Singleton A.B.; Taylor J.P.; Cookson M.R.; Restagno G.; Sabatelli M.; Bowser R.; Chi&#xF2; A.; Traynor B.J.; Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 2014,17(5),664-666","journal-title":"Nat Neurosci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"Neumann M.","year":"2006","unstructured":"Neumann M.; Sampathu D.M.; Kwong L.K.; Truax A.C.; Micsenyi M.C.; Chou T.T.; Bruce J.; Schuck T.; Grossman M.; Clark C.M.; McCluskey L.F.; Miller B.L.; Masliah E.; Mackenzie I.R.; Feldman H.; Feiden W.; Kretzschmar H.A.; Trojanowski J.Q.; Lee V.M.; Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006,314(5796),130-133","journal-title":"Science"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/brain\/awt029","volume":"136","author":"Iguchi Y.","year":"2013","unstructured":"Iguchi Y.; Katsuno M.; Niwa J.; Takagi S.; Ishigaki S.; Ikenaka K.; Kawai K.; Watanabe H.; Yamanaka K.; Takahashi R.; Misawa H.; Sasaki S.; Tanaka F.; Sobue G.; Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain 2013,136(Pt 5),1371-1382","journal-title":"Brain"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"15635","DOI":"10.1074\/jbc.M111.333450","volume":"287","author":"Colombrita C.","year":"2012","unstructured":"Colombrita C.; Onesto E.; Megiorni F.; Pizzuti A.; Baralle F.E.; Buratti E.; Silani V.; Ratti A.; TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem 2012,287(19),15635-15647","journal-title":"J Biol Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nn.2779","volume":"14","author":"Polymenidou M.","year":"2011","unstructured":"Polymenidou M.; Lagier-Tourenne C.; Hutt K.R.; Huelga S.C.; Moran J.; Liang T.Y.; Ling S.C.; Sun E.; Wancewicz E.; Mazur C.; Kordasiewicz H.; Sedaghat Y.; Donohue J.P.; Shiue L.; Bennett C.F.; Yeo G.W.; Cleveland D.W.; Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011,14(4),459-468","journal-title":"Nat Neurosci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn.2778","volume":"14","author":"Tollervey J.R.","year":"2011","unstructured":"Tollervey J.R.; Curk T.; Rogelj B.; Briese M.; Cereda M.; Kayikci M.; K&#xF6;nig J.; Hortob&#xE1;gyi T.; Nishimura A.L.; Zupunski V.; Patani R.; Chandran S.; Rot G.; Zupan B.; Shaw C.E.; Ule J.; Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 2011,14(4),452-458","journal-title":"Nat Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.mcn.2011.02.013","volume":"47","author":"Xiao S.","year":"2011","unstructured":"Xiao S.; Sanelli T.; Dib S.; Sheps D.; Findlater J.; Bilbao J.; Keith J.; Zinman L.; Rogaeva E.; Robertson J.; RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol Cell Neurosci 2011,47(3),167-180","journal-title":"Mol Cell Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1073\/pnas.1112427109","volume":"109","author":"Kawahara Y.","year":"2012","unstructured":"Kawahara Y.; Mieda-Sato A.; TDP-43 promotes microRNA biogenesis as a component of the drosha and dicer complexes. Proc Natl Acad Sci 2012,109(9),3347-3352","journal-title":"Proc Natl Acad Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/emboj.2010.310","volume":"30","author":"Ayala Y.M.","year":"2011","unstructured":"Ayala Y.M.; De Conti L.; Avenda&#xF1;o-V&#xE1;zquez S.E.; Dhir A.; Romano M.; D\u2019Ambrogio A.; Tollervey J.; Ule J.; Baralle M.; Buratti E.; Baralle F.E.; TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 2011,30(2),277-288","journal-title":"EMBO J"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"653","DOI":"10.15252\/embj.201489852","volume":"34","author":"Coelho M.B.","year":"2015","unstructured":"Coelho M.B.; Attig J.; Bellora N.; K&#xF6;nig J.; Hallegger M.; Kayikci M.; Eyras E.; Ule J.; Smith C.W.; Nuclear matrix protein matrin 3 regulates alternative splicing and forms overlapping regulatory networks with PTB. EMBO J 2015,34(5),653-668","journal-title":"EMBO J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e23882","DOI":"10.1371\/journal.pone.0023882","volume":"6","author":"Salton M.","year":"2011","unstructured":"Salton M.; Elkon R.; Borodina T.; Davydov A.; Yaspo M.L.; Halperin E.; Shiloh Y.; Matrin 3 binds and stabilizes mRNA. PLoS One 2011,6(8),e23882","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1021\/pr400193j","volume":"12","author":"Tenzer S.","year":"2013","unstructured":"Tenzer S.; Moro A.; Kuharev J.; Francis A.C.; Vidalino L.; Provenzani A.; Macchi P.; Proteome-wide characterization of the RNA-binding protein RALY-interactome using the in vivo-Biotinylation-Pulldown-Quant (iBioPQ) approach. J Proteome Res 2013,12(6),2869-2884","journal-title":"J Proteome Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e88217","DOI":"10.1371\/journal.pone.0088217","volume":"9","author":"Yamazaki F.","year":"2014","unstructured":"Yamazaki F.; Kim H.H.; Lau P.; Hwang C.K.; Iuvone P.M.; Klein D.; Clokie S.J.; pY RNA1-s2: A highly retina-enriched small RNA that selectively binds to Matrin 3 (Matr3). PLoS One 2014,9(2),e88217","journal-title":"PLoS One"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"36337","DOI":"10.1074\/jbc.M104236200","volume":"276","author":"Buratti E.","year":"2001","unstructured":"Buratti E.; Baralle F.E.; Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001,276(39),36337-36343","journal-title":"J Biol Chem"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1101\/gad.194829.112","volume":"26","author":"Avenda&#xF1;o-V&#xE1;zquez S.E.","year":"2012","unstructured":"Avenda&#xF1;o-V&#xE1;zquez S.E.; Dhir A.; Bembich S.; Buratti E.; Proudfoot N.; Baralle F.E.; Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative poly A site selection. Genes Dev 2012,26(15),1679-1684","journal-title":"Genes Dev"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1261\/rna.047647.114","volume":"21","author":"D\u2019Alton S.","year":"2015","unstructured":"D\u2019Alton S.; Altshuler M.; Lewis J.; Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis. RNA 2015,21(8),1419-1432","journal-title":"RNA"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nbd.2013.03.003","volume":"55","author":"Gerbino V.","year":"2013","unstructured":"Gerbino V.; Carr&#xEC; M.T.; Cozzolino M.; Achsel T.; Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm. Neurobiol Dis 2013,55,120-128","journal-title":"Neurobiol Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1073\/pnas.1506282112","volume":"112","author":"Yu Y.","year":"2015","unstructured":"Yu Y.; Reed R.; FUS functions in coupling transcription to splicing by mediating an interaction between RNAP II and U1 snRNP. Proc Natl Acad Sci USA 2015,112(28),8608-8613","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"7821","DOI":"10.1073\/pnas.1509744112","volume":"112","author":"Barmada S.J.","year":"2015","unstructured":"Barmada S.J.; Ju S.; Arjun A.; Batarse A.; Archbold H.C.; Peisach D.; Li X.; Zhang Y.; Tank E.M.; Qiu H.; Huang E.J.; Ringe D.; Petsko G.A.; Finkbeiner S.; Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci USA 2015,112(25),7821-7826","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/hmg\/dds526","volume":"22","author":"Daigle J.G.","year":"2013","unstructured":"Daigle J.G.; Lanson N.A.; Smith R.B.; Casci I.; Maltare A.; Monaghan J.; Nichols C.D.; Kryndushkin D.; Shewmaker F.; Pandey U.B.; RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet 2013,22(6),1193-1205","journal-title":"Hum Mol Genet"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1542\/peds.2013-4301","volume":"134","author":"Kidd S.A.","year":"2014","unstructured":"Kidd S.A.; Lachiewicz A.; Barbouth D.; Blitz R.K.; Delahunty C.; McBrien D.; Visootsak J.; Berry-Kravis E.; Fragile X syndrome: A review of associated medical problems. Pediatrics 2014,134(5),995-1005","journal-title":"Pediatrics"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.neuron.2013.02.022","volume":"77","author":"Nelson D.L.","year":"2013","unstructured":"Nelson D.L.; Orr H.T.; Warren S.T.; The unstable repeats-three evolving faces of neurological disease. Neuron 2013,77(5),825-843","journal-title":"Neuron"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"E5391","DOI":"10.1073\/pnas.1515737112","volume":"112","author":"Vasilyev N.","year":"2015","unstructured":"Vasilyev N.; Polonskaia A.; Darnell J.C.; Darnell R.B.; Patel D.J.; Serganov A.; Crystal structure reveals specific recognition of a G-quadruplex RNA by a &#x3B2;-turn in the RGG motif of FMRP. Proc Natl Acad Sci USA 2015,112(39),E5391-E5400","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"Darnell J.C.","year":"2011","unstructured":"Darnell J.C.; Van Driesche S.J.; Zhang C.; Hung K.Y.S.; Mele A.; Fraser C.E.; Stone E.F.; Chen C.; Fak J.J.; Chi S.W.; Licatalosi D.D.; Richter J.D.; Darnell R.B.; FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011,146(2),247-261","journal-title":"Cell"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1083\/jcb.201105092","volume":"197","author":"Orr H.T.","year":"2012","unstructured":"Orr H.T.; Cell biology of spinocerebellar ataxia. J Cell Biol 2012,197(2),167-177","journal-title":"J Cell Biol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1091\/mbc.e06-12-1120","volume":"18","author":"Nonhoff U.","year":"2007","unstructured":"Nonhoff U.; Ralser M.; Welzel F.; Piccini I.; Balzereit D.; Yaspo M-L.; Lehrach H.; Krobitsch S.; Ataxin-2 interacts with the DEAD\/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 2007,18(4),1385-1396","journal-title":"Mol Biol Cell"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/hmg\/ddl173","volume":"15","author":"Satterfield T.F.","year":"2006","unstructured":"Satterfield T.F.; Pallanck L.J.; Ataxin-2 and its drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet 2006,15(16),2523-2532","journal-title":"Hum Mol Genet"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.10R01FM","volume":"114","author":"Nishi A.","year":"2010","unstructured":"Nishi A.; Snyder G.L.; Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci 2010,114(1),6-16","journal-title":"J Pharmacol Sci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1152\/jn.2002.88.3.1270","volume":"88","author":"Lu Y.F.","year":"2002","unstructured":"Lu Y.F.; Hawkins R.D.; Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J Neurophysiol 2002,88(3),1270-1278","journal-title":"J Neurophysiol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/j.1460-9568.2011.07606.x","volume":"33","author":"Merz K.","year":"2011","unstructured":"Merz K.; Herold S.; Lie D.C.; CREB in adult neurogenesis-master and partner in the development of adult-born neurons? Eur J Neurosci 2011,33(6),1078-1086","journal-title":"Eur J Neurosci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","volume":"15","author":"Hanger D.P.","year":"2009","unstructured":"Hanger D.P.; Anderton B.H.; Noble W.; Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009,15(3),112-119","journal-title":"Trends Mol Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1074\/jbc.M110.204453","volume":"286","author":"Shi J.","year":"2011","unstructured":"Shi J.; Qian W.; Yin X.; Iqbal K.; Grundke-Iqbal I.; Gu X.; Ding F.; Gong C.X.; Liu F.; Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: A mechanism involved in tau pathology of Alzheimer\u2019s disease. J Biol Chem 2011,286(16),14639-14648","journal-title":"J Biol Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12035-010-8104-x","volume":"41","author":"Domek-\u0141opaci\u0144ska K.U.","year":"2010","unstructured":"Domek-\u0141opaci\u0144ska K.U.; Strosznajder J.B.; Cyclic GMP and nitric oxide synthase in aging and Alzheimer\u2019s disease. Mol Neurobiol 2010,41(2-3),129-137","journal-title":"Mol Neurobiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20062129","volume":"204","author":"Bopp T.","year":"2007","unstructured":"Bopp T.; Becker C.; Klein M.; Klein-Hessling S.; Palmetshofer A.; Serfling E.; Heib V.; Becker M.; Kubach J.; Schmitt S.; Stoll S.; Schild H.; Staege M.S.; Stassen M.; Jonuleit H.; Schmitt E.; Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007,204(6),1303-1310","journal-title":"J Exp Med"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1027362629161","volume":"17","author":"Dong R.P.","year":"1997","unstructured":"Dong R.P.; Umezawa Y.; Ikushima H.; Munakata Y.; Schlossman S.F.; Morimoto C.; Different regulatory effects of pentoxifylline on human T cell activation pathways. J Clin Immunol 1997,17(3),247-252","journal-title":"J Clin Immunol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00000198","volume":"49","author":"Silva J.C.R.","year":"2000","unstructured":"Silva J.C.R.; Rocha M.F.G.; Lima A.A.M.; Brito G.A.C.; De Menezes D.B.; Rao V.S.N.; Effects of pentoxifylline and nabumetone on the serum levels of IL-1&#x3B2; and TNFalpha in rats with adjuvant arthritis. Inflamm Res 2000,49(1),14-19","journal-title":"Inflamm Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"Bollen E.","year":"2012","unstructured":"Bollen E.; Prickaerts J.; Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012,64(12),965-970","journal-title":"IUBMB Life"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"Bender A.T.","year":"2006","unstructured":"Bender A.T.; Beavo J.A.; Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006,58(3),488-520","journal-title":"Pharmacol Rev"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","volume":"182","author":"P&#xE9;rez-Torres S.","year":"2003","unstructured":"P&#xE9;rez-Torres S.; Cort&#xE9;s R.; Tolnay M.; Probst A.; Palacios J.M.; Mengod G.; Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer\u2019s disease brains examined by in situ hybridization. Exp Neurol 2003,182(2),322-334","journal-title":"Exp Neurol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ana.410190306","volume":"19","author":"Brun A.","year":"1986","unstructured":"Brun A.; Englund E.; A white matter disorder in dementia of the Alzheimer\u2019s type: A pathoanatomical study. Ann Neurol 1986,19(3),253-262","journal-title":"Ann Neurol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jneuroim.2009.12.012","volume":"220","author":"Mizrachi K.","year":"2010","unstructured":"Mizrachi K.; Aricha R.; Feferman T.; Kela-Madar N.; Mandel I.; Paperna T.; Miller A.; Ben-Nun A.; Berrih-Aknin S.; Souroujon M.C.; Fuchs S.; Involvement of phosphodiesterases in autoimmune diseases. J Neuroimmunol 2010,220(1-2),43-51","journal-title":"J Neuroimmunol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"15124","DOI":"10.1073\/pnas.0602795103","volume":"103","author":"Wong M-L.","year":"2006","unstructured":"Wong M-L.; Whelan F.; Deloukas P.; Whittaker P.; Delgado M.; Cantor R.M.; McCann S.M.; Licinio J.; Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006,103(41),15124-15129","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajhg.2009.12.003","volume":"86","author":"Appenzeller S.","year":"2010","unstructured":"Appenzeller S.; Schirmacher A.; Halfter H.; B&#xE4;umer S.; Pendziwiat M.; Timmerman V.; De Jonghe P.; Fekete K.; St&#xF6;gbauer F.; L&#xFC;demann P.; Hund M.; Quabius E.S.; Ringelstein E.B.; Kuhlenb&#xE4;umer G.; Autosomal-dominant striatal degeneration is caused by a mutation in the phosphodiesterase 8B gene. Am J Hum Genet 2010,86(1),83-87","journal-title":"Am J Hum Genet"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.neuroscience.2005.01.050","volume":"132","author":"Reyes-Irisarri E.","year":"2005","unstructured":"Reyes-Irisarri E.; P&#xE9;rez-Torres S.; Mengod G.; Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005,132(4),1173-1185","journal-title":"Neuroscience"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archneur.64.3.456","volume":"64","author":"McLachlan C.S.","year":"2007","unstructured":"McLachlan C.S.; Chen M.L.; Lynex C.N.; Goh D.L.M.; Brenner S.; Tay S.K.H.; Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer\u2019s disease. Arch Neurol 2007,64,456-457","journal-title":"Arch Neurol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"Lakics V.","year":"2010","unstructured":"Lakics V.; Karran E.H.; Boess F.G.; Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010,59(6),367-374","journal-title":"Neuropharmacology"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","volume":"14","author":"Polli J.W.","year":"1994","unstructured":"Polli J.W.; Kincaid R.L.; Expression of calmodulin-dependent Phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci 1994,14(3),1251-1261","journal-title":"J Neurosci"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.4137\/GRSB.S13204","volume":"7","author":"Satoh J.","year":"2013","unstructured":"Satoh J.; Kawana N.; Yamamoto Y.; Pathway analysis of ChIPSeq-  based NRF1 target genes suggests a logical hypothesis of their  involvement in the pathogenesis of neurodegenerative diseases.  Gene Regul. Sys. Biol S132042013,7"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"e45457","DOI":"10.7554\/eLife.45457","volume":"8","author":"Silva M.C.","year":"2019","unstructured":"Silva M.C.; Ferguson F.M.; Cai Q.; Donovan K.A.; Nandi G.; Patnaik D.; Zhang T.; Huang H.T.; Lucente D.E.; Dickerson B.C.; Mitchison T.J.; Fischer E.S.; Gray N.S.; Haggarty S.J.; Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife 2019,8,e45457","journal-title":"eLife"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"112949","DOI":"10.1016\/j.ejmech.2020.112949","volume":"210","author":"Jiang X.","year":"2021","unstructured":"Jiang X.; Zhou J.; Wang Y.; Liu X.; Xu K.; Xu J.; Feng F.; Sun H.; PROTACs suppression of GSK-3&#x3B2;, a crucial kinase in neurodegenerative diseases. Eur J Med Chem 2021,210,112949","journal-title":"Eur J Med Chem"}],"container-title":["Central Nervous System Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871524922666220616092132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206062\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871524922666220616092132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:50:03Z","timestamp":1665402603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206062\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871524922666220616092132","relation":{},"ISSN":["1871-5249"],"issn-type":[{"value":"1871-5249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}